Non adherence to lipid-lowering therapy and strategies to improve adherence
Open accessAbstract
Lipid lowering therapies is well-established to prevent cardiovascular events in adults with dyslipidemia and multiple risk factors. However, global clinical usage of LLT,particularly statins remains suboptimal, with adherence low rates for primary prevention and secondary prevention. Low adherence is influenced by concerns about side effects, misconceptions about benefits. Patients often discontinue statins due to perceived side effects, despite clinical trials showing no increase in symptoms compared to placebo. Poor understanding of statin benefits, doubts about their necessity, and suspicions of over prescription contribute to nonadherence, which is often amplified by negative portrayal of LLT specialy statins on social media. Strategies to improve adherence include addressing patient concerns, enhancing physician-patient communication, and increasing patient education. Optimizing statin usage and reducing the burden of cardiovascular disease necessitates addressing patient perceptions and improving communication between healthcare providers and patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Reasons for poor adherence to lipid-lowering medications are multifactorial, including polypharmacy, lack of understanding of why LLMs are needed, fear of side effects, and misconceptions about hypercholesterolaemia as a condition requiring medication.
“Reasons for poor adherence to LLMs are multifactorial in nature. Polypharmacy, a lack of understanding of why LLMs are needed, fear of true or perceived side effects, misconceptions about hypercholesterolaemia as a condition requiring medication, are all factors which can compromise adherence.4”
From Interventions to improve adherence to lipid-lowering drugs: a systematic review and meta-analysis (2025) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bradley, C. K., Wang, T. Y., Li, S., Robinson, J. G., Roger, V. L., Goldberg, A. C., Virani, S. S., Louie, M. J., Lee, L. V., Peterson, E. D., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011765 · Cited by 286 · see citing works
Flagged first, then by citations
Research works printed but not linked: 24
- [1]Catapano A.L. Graham I. De Backer G. ESC/EAS guidelines for the management of dyslipidaemias Eur Heart J 37 39 2016 2999 3058 2016 27567407
- [2]Al-Omran M. Mamdani M.M. Lindsay T.F. Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study J Vasc Surg 48 3 2008 607 612 18585886
- [3]Fung V. Graetz I. Reed M. Jaffe M.G. Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk PLoS One 13 2 2018 e0191817 10.1371/journal.pone.0191817 [PMC free article] [PubMed] [CrossRef] [Google Scholar] PMC5805247 29420613 · DOI
- [4]Otto C.M. Statins for primary prevention of cardiovascular disease BMJ 355 2016 i6334 27884825
- [5]Stone N.J. Robinson J.G. Lichtenstein A.H. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline Ann Intern Med 160 5 2014 339 343 24474185
- [6]Tziomalos K. Athyros V.G. Mikhailidis D.P. Statin discontinuation: an underestimated risk? Curr Med Res Opin 24 11 2008 3059 3062 18826752
- [7]Gomez Sandoval Y.H. Braganza M.V. Daskalopoulou S.S. Statin discontinuation in high-risk patients: a systematic review of the evidence Curr Pharmaceut Des 17 33 2011 3669 3689 22074437
- [8]Naderi S.H. Bestwick J.P. Wald D.S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients Am J Med 125 9 2012 882 887.e1 22748400
- [9]Umarje S. James N.M. Dave P. Raut A. Pandey N. Impact of adherence, patient perception, and Knowledge to statin therapy - a cross-sectional study Indian J Endocrinol Metab 25 3 2021 May-Jun 206 210 10.4103/ijem.ijem_120_21 Epub 2021 Oct 26. PMID: 34760675; PMCID: PMC8547405 34760675 PMC8547405 · DOI
- [10]Ofori-Asenso R. Jakhu A. Zomer E. Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis J Gerontol A Biol Sci Med Sci 2017 10.1093/gerona/glx169 28958039 · DOI · Paper page
- [11]Aubert R.E. Yao J. Xia F. Garavaglia S.B. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care 16 6 2010 459 466 20560689
- [12]Jacobson T.A. NLA Task Force on statin safety — 2014 update J Clin Lipidol 8 3 Suppl 2014 S1 S4 24793438
- [13]Laufs U. Scharnagl H. Halle M. Treatment options for statin-associated muscle symptoms Dtsch Arztebl Int 112 44 2015 748 755 26575138 PMC4650909
- [14]Gencer B. Rodondi N. Auer R. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes Eur J Intern Med 26 1 2015 56 62 25582072
- [15]Harrison T.N. Derose S.F. Cheetham T.C. Primary nonadherence to statin therapy: patients' perceptions Am J Manag Care 19 4 2013 e133 e139 23725451
- [16]Silvennoinen R. Turunen J.H. Kovanen P.T. Attitudes and actions: a survey to assess statin use among Finnish patients with increased risk for cardiovascular events J Clin Lipidol 11 2 2017 485 494 28502506
- [17]Nihar R. Desai M.D. Mph Michael Farbaniec M.D. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients Clinical Cardiology, Volume46, Issue1 January 2023 PMC9849440 36267039
- [19]Golder S. O'Connor K. Hennessy S. Gross R. Gonzalez-Hernandez G. Assessment of beliefs and attitudes about statins posted on twitter: a qualitative study JAMA Netw Open 3 6 2020 Jun 1 e208953 10.1001/jamanetworkopen.2020.8953 PMCID: PMC7317605PMID: 32584408 PMC7317605 32584408 · DOI
- [20]Krishnamurthy A. Bradley C. Ascunce R. SAMSON and the Nocebo effect: management of statin intolerance Curr Cardiol Rep 24 2022 1101 1108 35759168
- [21]Nelson A.J. Puri R. Nissen S.E. Statins in a distorted mirror of media Curr Atherosclerosis Rep 22 8 2020 Jun 18 37 10.1007/s11883-020-00853-9 PMID: 32557172 32557172 · DOI
- [22]Chee Y. Chan V. Tan N. Understanding patients' perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review Singap Med J 55 8 2014 416 421 10.11622/smedj.2014099 PMC4294090 25189302 · DOI
- [23]Lemstra M. Blackburn D. Crawley A. Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis Can J Cardiol 28 5 2012 574 580 10.1016/j.cjca.2012.05.007 22884278 · DOI
- [24]Bohan H. van Doorn T. Witwicki C. Coulter A. Perceptions of Statins. Research with Patients, GPs and Cardiologists 2015 Picker Institute Europe Oxford
- [25]Rea F. Biffi A. Ronco R. Cardiovascular outcomes and mortality associated with discontinuing statins in older patients receiving polypharmacy JAMA Netw Open 4 6 2021 e2113186 10.1001/jamanetworkopen.2021.13186 PMC8204202 34125221 · DOI
Cited by
Sorted by citations
Interventions to improve adherence to lipid-lowering drugs: a systematic review and meta-analysis
Yow, D. K. W., Ang, W. J., Yap, H. J., Ito, S., Liu, J., Ko, J., Tan, D. S.-Y., Lorenzatti, A., & Ang, C.-S. (2025) · eClinicalMedicine · doi:10.1016/j.eclinm.2025.103270 · Cited by 5 · see citing works
- Authors
- Mehta, A.
- Affiliations
- Sir Ganga Ram Hospital (IN)
- Corresponding author
- Mehta, Ashwani
- ORCID
- Mehta, Ashwani
- Venue
- Indian Heart Journal
- Publisher
- Elsevier BV
- Published
- 2024-03
- Volume
- 76
- Pages
- S138-S140
- ISSN
- 0019-4832 (ISSN-L)
- PMC
- PMC11019324
- OpenAlex
- W4390779397
- Cited by
- 6
- References
- 1
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Indian Heart Journal (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Health Professions › General Health Professions › Patient-Provider Communication in Healthcare
- Keywords
- medication non-adherence, lipid-lowering therapy, statins, dyslipidemia, cardiovascular risk reduction, statin adverse effects, patient perspectives, physician-patient communication, patient education, social media influence, primary and secondary prevention
- MeSH terms
- Adult, Cardiovascular Diseases, Humans, Lipids, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
